Effects of varying antigens and adjuvant systems on the immunogenicity and safety of investigational tetravalent human oncogenic papillomavirus vaccines: Results from two randomized trials

Vaccine

Volumn 32, Issue 29, 2014, Pages 3694-3705

  Van Damme, Pierre ^a   Leroux Roels, Geert ^b   Simon, Philippe ^c   Foidart, Jean Michel ^d,j   Donders, Gilbert ^e,k   Hoppenbrouwers, Karel ^f   Levin, Myron ^g   Tibaldi, Fabian ^h   Poncelet, Sylviane ^h   Moris, Philippe ^h   Dessy, Francis ^h   Giannini, Sandra L ^h   Descamps, Dominique ^h   Dubin, Gary ⁱ  

^a UNIVERSITY OF ANTWERP   (Belgium)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c ERASME HOSPITAL   (Belgium)

^d Centre Hospitalier Regional de La Citadelle   (Belgium)

^e Gynaecologie Heilig Hartziekenhuis   (Belgium)

^f UNIVERSITY OF LEUVEN   (Belgium)

^g UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^h GSK   (Belgium)

ⁱ GLAXOSMITHKLINE   (United States)

^j UNIVERSITY OF LIÈGE   (Belgium)

^k ANTWERP UNIVERSITY HOSPITAL   (Belgium)

more..

Author keywords

Bivalent vaccine; Human papillomavirus vaccine; Immune interference; Immunogenicity; Safety; Tetravalent vaccine

Indexed keywords

ADJUVANT; ASO1 VACCINE; ASO2 VACCINE; ASO4 VACCINE; CROSS REACTING ANTIBODY; TETRAVALENT HPV 16 18 31 45 AS04 VACCINE; TETRAVALENT HPV 16 18 33 58 VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS LIKE PARTICLE VACCINE; WART VIRUS VACCINE; HUMAN PAPILLOMAVIRUS VACCINE, L1 TYPE 16, 18; IMMUNOLOGICAL ADJUVANT; NEW DRUG;

ADULT; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; AUTOIMMUNE DISEASE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; DRUG DOSE REGIMEN; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; HUMAN EXPERIMENT; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 45; HUMAN PAPILLOMAVIRUS TYPE 58; IMMUNOGENICITY; INJECTION SITE PAIN; MEMORY CELL; MYELITIS; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SKIN PRURITUS; VACCINATION; VIRUS LIKE AGENT; ADOLESCENT; ANTIBODY PRODUCTION; B LYMPHOCYTE; BELGIUM; BLOOD; CLINICAL TRIAL; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; IMMUNOLOGICAL MEMORY; IMMUNOLOGY; MULTICENTER STUDY; PAPILLOMAVIRUS INFECTIONS; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VIROLOGY; YOUNG ADULT;

ADJUVANTS, IMMUNOLOGIC; ADOLESCENT; ADULT; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, VIRAL; B-LYMPHOCYTES; BELGIUM; DOSE-RESPONSE RELATIONSHIP, IMMUNOLOGIC; DOUBLE-BLIND METHOD; DRUGS, INVESTIGATIONAL; FEMALE; HUMAN PAPILLOMAVIRUS 16; HUMAN PAPILLOMAVIRUS 18; HUMANS; IMMUNOLOGIC MEMORY; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VACCINES, VIRUS-LIKE PARTICLE; YOUNG ADULT;

EID: 84901606214     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.03.040     Document Type: Article

References (31)

1. Ferlay J., Shin H.R., Bray F., Forman D., Mathers C., Parkin D.M. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 2010, International Agency for Research on Cancer, Lyon, France, Available from: http://globocan.iarc.fr [accessed 07.05.12, Internet].
2. Walboomers J.M., Jacobs M.V., Manos M.M., Bosch F.X., Kummer J.A., Shah K.V., et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999, 189:12-19.
3. Bosch F.X., Burchell A.N., Schiffman M., Giuliano A.R., de Sanjose S., Bruni L., et al. Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia. Vaccine 2008, 26(Suppl. 10):K1-K16.
4. Li N., Franceschi S., Howell-Jones R., Snijders P.J., Clifford G.M. Human papillomavirus type distribution in 30,848 invasive cervical cancers worldwide: variation by geographical region, histological type and year of publication. Int J Cancer 2010, 128:927-935.
5. Schiffman M., Clifford G., Buonaguro F.M. Classification of weakly carcinogenic human papillomavirus types: addressing the limits of epidemiology at the borderline. Infect Agent Cancer 2009, 4:8.
6. Guan P., Howell-Jones R., Li N., Bruni L., de Sanjosé S., Franceschi S., et al. Human papillomavirus types in 115,789 HPV-positive women: a meta-analysis from cervical infection to cancer. Int J Cancer 2012, 131:2349-2359.
7. Paavonen J., Naud P., Salmeron J., Wheeler C.M., Chow S.N., Apter D., et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet 2009, 374:301-314.
8. Wheeler C.M., Castellsague X., Garland S.M., Szarewski A., Paavonen J., Naud P., et al. Cross-protective efficacy of HPV-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by non-vaccine oncogenic HPV types: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:100-110.
9. Brown D.R., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Wheeler C.M., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis 2009, 199:926-935.
10. Wheeler C.M., Kjaer S.K., Sigurdsson K., Iversen O.E., Hernandez-Avila M., Perez G., et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years. J Infect Dis 2009, 199:936-944.
11. Lehtinen M., Paavonen J., Wheeler C.M., Jaisamrarn U., Garland S.M., Castellsague X., et al. Overall efficacy of HPV-16/18 AS04-adjuvanted vaccine against grade 3 or greater cervical intraepithelial neoplasia: 4-year end-of-study analysis of the randomised, double-blind PATRICIA trial. Lancet Oncol 2012, 13:89-99.
12. Garçon N., Morel S., Didierlaurent A., Descamps D., Wettendorff M., Van Mechelen M. Development of an AS04-adjuvanted HPV vaccine with the adjuvant system approach. BioDrugs 2011, 25:217-226.
13. Garçon N., Van Mechelen M. Recent clinical experience with vaccines using MPL- and QS-21-containing adjuvant systems. Expert Rev Vaccines 2011, 10:471-486.
14. Dessy F.J., Giannini S.L., Bougelet C.A., Kemp T.J., David M.P., Poncelet S.M., et al. Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine. Hum Vaccin 2008, 4:425-434.
15. Pastrana D.V., Buck C.B., Pang Y.Y., Thompson C.D., Castle P.E., FitzGerald P.C., et al. Reactivity of human sera in a sensitive, high-throughput pseudovirus-based papillomavirus neutralization assay for HPV16 and HPV18. Virology 2004, 321:205-216.
16. ® human papillomavirus (HPV) cervical cancer vaccines in healthy women aged 18-45 years. Hum Vaccin 2009, 5:705-719.
17. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparative immunogenicity and safety of human papillomavirus (HPV)-16/18 vaccine and HPV-6/11/16/18 vaccine: follow-up from months 12-24 in a Phase III randomized study of healthy women aged 18-45 years. Hum Vaccin 2011, 7:1343-1358.
18. Harper D.M., Franco E.L., Wheeler C., Ferris D.G., Jenkins D., Schuind A., et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial. Lancet 2004, 364:1757-1765.
19. Paavonen J., Jenkins D., Bosch F.X., Naud P., Salmeron J., Wheeler C.M., et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007, 369:2161-2170.
20. Einstein M.H., Baron M., Levin M.J., Chatterjee A., Fox B., Scholar S., et al. Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18-45 years. Hum Vaccin 2011, 7:1359-1373.
21. Patriarca P.A., Wright P.F., John T.J. Factors affecting the immunogenicity of oral poliovirus vaccine in developing countries: review. Rev Infect Dis 1991, 13:926-939.
22. Bar-On E.S., Goldberg E., Fraser A., Vidal L., Hellmann S., Leibovici L. Combined DTP-HBV-HIB vaccine versus separately administered DTP-HBV and HIB vaccines for primary prevention of diphtheria, tetanus, pertussis, hepatitis B and Haemophilus influenzae B (HIB). Cochrane Database Syst Rev 2009, (3):CD005530.
23. Schneerson R., Robbins J.B., Parke J.C., Bell C., Schlesselman J.J., Sutton A., et al. Quantitative and qualitative analyses of serum antibodies elicited in adults by Haemophilus influenzae type b and pneumococcus type 6A capsular polysaccharide-tetanus toxoid conjugates. Infect Immun 1986, 52:519-528.
24. Joines R.W., Blatter M., Abraham B., Xie F., De Clercq N., Baine Y., et al. A prospective, randomized, comparative US trial of a combination hepatitis A and B vaccine (Twinrix) with corresponding monovalent vaccines (Havrix and Engerix-B) in adults. Vaccine 2001, 19:4710-4719.
25. Kallinowski B., Knoll A., Lindner E., Sanger R., Stremmel W., Vollmar J., et al. Can monovalent hepatitis A and B vaccines be replaced by a combined hepatitis A/B vaccine during the primary immunization course?. Vaccine 2000, 19:16-22.
26. Connor B.A., Blatter M.M., Beran J., Zou B., Trofa A.F. Rapid and sustained immune response against hepatitis A and B achieved with combined vaccine using an accelerated administration schedule. J Travel Med 2007, 14:9-15.
27. Rizk R.Z., Christensen N.D., Michael K.M., et al. Reactivity pattern of 92 monoclonal antibodies with 15 human papillomavirus types. J Gen Virol 2008, 89:117-129.
28. Safaeian M., Porras C., Schiffman M., Rodriguez A.C., Wacholder S., Gonzalez P., et al. Epidemiological study of anti-HPV16/18 seropositivity and subsequent risk of HPV16 and -18 infections. J Natl Cancer Inst 2010, 102:1653-1662.
29. Kemp T.J., Hildesheim A., Safaeian M., Dauner J.G., Pan Y., Porras C., et al. HPV16/18 L1 VLP vaccine induces cross-neutralizing antibodies that may mediate cross-protection. Vaccine 2011, 29:2011-2014.
30. Romanowski B., Schwarz T.F., Ferguson L.M., Peters K., Dionne M., Schulze K., et al. Immunogenicity and safety of the HPV-16/18 AS04-adjuvanted vaccine administered as a 2-dose schedule compared to the licensed 3-dose schedule: results from a randomized study. Hum Vaccin 2011, 7:1374-1386.
31. Kreimer A.R., Rodriguez A.C., Hildesheim A., Herrero R., Porras C., Schiffman M., et al. Proof-of-principle evaluation of the efficacy of fewer than three doses of a bivalent HPV16/18 vaccine. J Natl Cancer Inst 2011, 103:1444-1451.